-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DXR/N4XirziTvH8UWGcuCKp8sIN34j3fpr+zsSA0KSpAFPB/ai+YnIotg8Ikt8/x 2lbhPAouj69ELh/94UR9TA== /in/edgar/work/20000607/0000919574-00-000599/0000919574-00-000599.txt : 20000919 0000919574-00-000599.hdr.sgml : 20000919 ACCESSION NUMBER: 0000919574-00-000599 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000607 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PENWEST PHARMACEUTICALS CO CENTRAL INDEX KEY: 0001047188 STANDARD INDUSTRIAL CLASSIFICATION: [2834 ] IRS NUMBER: 911513032 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-55303 FILM NUMBER: 651000 BUSINESS ADDRESS: STREET 1: 2981 ROUTE 22 CITY: PATTERSON STATE: NY ZIP: 12563-9970 BUSINESS PHONE: 9148783414 MAIL ADDRESS: STREET 1: 2981 ROUTE 22 STREET 2: 2981 ROUTE 22 CITY: PATTERSON STATE: NY ZIP: 12563-9970 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CURRAN JOHN P CENTRAL INDEX KEY: 0000026256 STANDARD INDUSTRIAL CLASSIFICATION: [ ] FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: CURRAN PARTNERS LP STREET 2: 230 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2128082400 MAIL ADDRESS: STREET 1: CURRAN PARTNERS LP STREET 2: 230 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 1010017 SC 13G/A 1 0001.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1 Name of Issuer: Penwest Pharmaceuticals Co. Inc. Title of Class of Securities: Common Stock, $.01 par value CUSIP Number: 709754105 (Date of Event Which Requires Filing of this Statement) December 31, 1999 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) /X/ Rule 13d-1(c) / / Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 709754105 1. Name of Reporting Person I.R.S. Identification No. of Above Person John P. Curran 2. Check the Appropriate Box if a Member of a Group a. b. 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 254,300 6. Shared Voting Power: 811,250 7. Sole Dispositive Power: 254,300 8. Shared Dispositive Power: 811,250 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,065,550 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares -2- 11. Percent of Class Represented by Amount in Row (9) 8.5% 12. Type of Reporting Person IN -3- CUSIP Number: 709754105 1. Name of Reporting Person I.R.S. Identification No. of Above Person Curran Partners, L.P. 2. Check the Appropriate Box if a Member of a Group a. b. 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 6. Shared Voting Power: 811,250 7. Sole Dispositive Power: 8. Shared Dispositive Power: 811,250 9. Aggregate Amount Beneficially Owned by Each Reporting Person 811,250 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares -4- 11. Percent of Class Represented by Amount in Row (9) 6.4% 12. Type of Reporting Person PN -5- Item 1(a) Name of Issuer: PenWest Pharmaceuticals Co. (b) Address of Issuer's Principal Executive Offices: 2981 Route 22 Patterson, NY 12563-9970 Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons Filing: The principal address of John P. Curran and Curran Partners, L.P. (the "Partnership") is 237 Park Avenue, New York, New York 10017. John P. Curran is a United States citizen. The Partnership is a Delaware limited partnership. (d) Title of Class of Securities: Common Stock, $.01 par value (the "Common Stock") (e) CUSIP Number: 709754105 Item 3. If this statement is filed pursuant to Rule 13d-1(b)(1) or 13d-2(b) or (c) check whether the person filing is: (a) / / Broker or dealer registered under Section 15 of the Act, (b) / / Bank as defined in Section 3(a)(6) of the Act, (c) / / Insurance Company as defined in Section 3(a)(19) of the Act, (d) / / Investment Company registered under Section 8 of the Investment Company Act, (e) / / Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940, (f) / / Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund, (g) / / Parent Holding Company, in accordance with Rule 13d-1(b)(ii)(G), -6- (h) / / Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act, (i) / / Church plan excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act, (j) / / Group, in accordance with Rule 13d- 1(b)(1)(ii)(H). If this statement is filed pursuant to Rule 13d-1(c), check this box. /X/ Item 4. Ownership. (a) Amount Beneficially Owned: Mr. Curran owns 1,065,550 shares of Common Stock; the Partnership owns 811,250 shares of Common Stock. (b) Percent of Class: Mr. Curran's shares represent 8.5% of the outstanding Common Stock; the Partnership's shares represent 6.4% of the outstanding Common Stock. (c) Mr. Curran: 254,300 shares with sole power to vote or to direct the vote; 811,250 shares with shared power to vote or to direct the vote; 254,300 shares with sole power to dispose or of which to direct the disposition; 811,250 shares with shared power to dispose or of which to direct the disposition. The Partnership: 0 shares with sole power to vote or to direct the vote; 811,250 shares with shared power to vote or to direct the vote; 0 shares with sole power to dispose or of which to direct the disposition; 811,250 shares with shared power to dispose or of which to direct the disposition. Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not Applicable -7- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of the Group. Not Applicable Item 10. Certification for Rule 13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. /s/ John P. Curran June 7, 2000 ______________________ ___________________ JOHN P. CURRAN Date CURRAN PARTNERS, L.P. By: /s/ John P. Curran June 7, 2000 _________________________ ___________________ Title: General Partner Date -8- AGREEMENT The undersigned agree that this Schedule 13G dated June 7, 2000 relating to the Common Stock of Penwest Pharmacueticals Co. Inc. shall be filed on behalf of the undersigned. CURRAN PARTNERS, L.P. By: /s/ John P. Curran ________________________ John P. Curran General Partner /s/ John P. Curran _________________________ John P. Curran -9- 16160000.AH3 -----END PRIVACY-ENHANCED MESSAGE-----